CARINA interim analysis: A non-interventional study of real-world treatment sequencing and outcomes in patients with advanced renal cell carcinoma initiated on first-line checkpoint inhibitor-based combination therapy.

被引：0
|
作者：
Nathan, Paul D.
Allison, Jennifer
Charnley, Natalie
Michael, Agnieszka
Moore, Kathryn
Sharma, Anand
Klair, Bhupinder
Perrot, Valerie
Larkin, James
机构：
[1] Mt Vernon Canc Ctr, Northwood, Middx, England
[2] Christie NHS Fdn Trust, Manchester, Lancs, England
[3] Royal Preston Hosp, Preston, Lancs, England
[4] Royal Surrey Cty Hosp NHS Fdn Trust, Guildford, Surrey, England
[5] Nottingham Univ Hosp NHS Trust, Nottingham, England
[6] East & North Hertfordshire NHS Trust, Mt Vernon Canc Ctr, Northwood, Middx, England
[7] Ipsen, Slough, Berks, England
[8] Ipsen, Boulogne Billancourt, France
[9] Royal Marsden Hosp NHS Fdn Trust, London, England
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
626
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Real-world Treatment Sequencing and Outcomes With Cabozantinib After First-line Immune Checkpoint Inhibitor-based Combination Therapy For Patients With Advanced Renal Cell Carcinoma: CARINA Study Results
    Nathan, Paul
    Venugopal, Balaji
    Ali, Jamshed
    Allison, Jennifer
    Ceruso, Mariangela
    Charnley, Natalie
    Griffiths, Richard
    Michael, Agnieszka
    Moore, Kathryn
    Perrot, Valerie
    Prendergast, Aine
    Sharma, Anand
    Szabados, Bernadett
    Larkin, James
    CLINICAL GENITOURINARY CANCER, 2024, 22 (05)
  • [2] Real-world treatment sequencing and outcomes for patients with advanced renal cell carcinoma treated with cabozantinib after first-line checkpoint inhibitor-based combination therapy: Results from the CARINA study
    Nathan, Paul D.
    Allison, Jennifer
    Charnley, Natalie
    Griffiths, Richard
    Michael, Agnieszka
    Moore, Kathryn
    Sharma, Anand
    Szabados, Bernadett
    Venugopal, Balaji
    Ali, Jamshed
    Perrot, Valerie
    Prendergast, Aine
    Klair, Bhupinder
    Larkin, James
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [3] Non-interventional study on first-line therapy in advanced renal cell carcinoma
    Rexer, H.
    Merseburger, A.
    Doehn, C.
    UROLOGIE, 2023, 62 (02): : 220 - 221
  • [4] Non-interventional Study in advanced Renal Cell Carcinoma in First-line Therapy
    Rexer, H.
    Grimm, M. -O.
    Steiner, T.
    AKTUELLE UROLOGIE, 2020, 51 (06) : 528 - 529
  • [5] Non-interventional study of first-line therapy in advanced or metastatic renal cell carcinoma
    Rexer, Heidrun
    Wunderlich, Heiko
    Doehn, Christian
    AKTUELLE UROLOGIE, 2024, 55 (03)
  • [6] FIRST-LINE THERAPY FOR MULTIPLE MYELOMA (MM): RESULTS FROM THE SECOND INTERIM ANALYSIS OF THE REAL-WORLD, INTERNATIONAL, NON-INTERVENTIONAL EMMOS STUDY
    Mohty, M.
    Terpos, E.
    Mateos, M. V.
    Palumbo, A.
    Lejniece, S.
    Beksac, M.
    Bekadja, M. A.
    Legiec, W.
    Dimopoulos, M.
    Stankovic, S.
    Duran, M. S.
    De Stefano, V.
    Kochkareva, Y.
    Laane, E.
    Berthou, C.
    Salwender, H.
    Masliak, Z.
    Peceliunas, V.
    Willenbacher, W.
    Silva, J.
    Louw, V.
    Nemet, D.
    Borbenyi, Z.
    Abadi, U.
    Pedersen, R. S.
    Cernelc, P.
    Potamianou, A.
    Couturier, C.
    Olie, R.
    Feys, C.
    Thoret-Bauchet, F.
    Boccadoro, M.
    HAEMATOLOGICA, 2014, 99 : 360 - 361
  • [7] Outcomes of patients with advanced non-clear cell renal cell carcinoma treated with first-line immune checkpoint inhibitor therapy
    Graham, Jeffrey
    Wells, John Connor
    Dudani, Shaan
    Gan, Chun L.
    Donskov, Frede
    Lee, Jae-Lyun
    Kollmannsberger, Christian K.
    Meza, Luis
    Beuselinck, Benoit
    Hansen, Aaron
    North, Scott A.
    Bjarnason, Georg A.
    Sayegh, Nicolas
    Kanesvaran, Ravindran
    Wood, Lori A.
    Hotte, Sebastien J.
    McKay, Rana R.
    Choueiri, Toni K.
    Heng, Daniel Y. C.
    EUROPEAN JOURNAL OF CANCER, 2022, 171 : 124 - 132
  • [8] First-Line Immune Checkpoint Inhibitor-Based Therapy for Metastatic Renal Cell Carcinoma: A Systematic Review
    Thana, Myuran
    Wood, Lori Anne
    KIDNEY CANCER, 2020, 4 (02) : 81 - 92
  • [9] Final analysis of a non-interventional study on cabozantinib in patients with advanced renal cell carcinoma after prior checkpoint inhibitor therapy (CaboCHECK).
    Grunwald, Viktor
    Boegemann, Martin
    Rafiyan, Mohammad-Reza
    Niegisch, Guenter
    Schnabel, Marco Julius
    Florcken, Anne
    Maintz, Christoph
    Zahn, Mark-Oliver
    Wortmann, Anke
    Hinkel, Andreas
    Casper, Jochen
    Darr, Christopher
    Hilser, Thomas
    Schulze, Matthias
    Sookthai, Disorn
    Schoenherr, Caroline
    Ivanyi, Philipp
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06)
  • [10] Real-World Outcomes in Patients with Advanced/Metastatic Renal Cell Carcinoma Receiving Cabozantinib or Other Tyrosine Kinase Inhibitors After Checkpoint Inhibitor-Based Therapy
    Heng, Daniel Y. C.
    Doshi, Gurjyot K.
    Dutailly, Pascale
    Houchard, Aude
    Lothgren, Mickael
    Monnette, Alisha
    Wang, Yunfei
    Perrot, Valerie
    Lalani, Aly-Khan A.
    KIDNEY CANCER, 2024, 8 (01) : 99 - 114
12345